Navigation Links
CryoLife Announces First Clinical Use of BioFoam(R)
Date:9/10/2009

ATLANTA and LONDON, Sept. 10 /PRNewswire-FirstCall/ -- CryoLife, Inc., (NYSE: CRY) an implantable biological medical device and cardiovascular tissue processing company, today announced the first clinical implant of its BioFoam(R) Surgical Matrix, which received CE mark approval in August 2009. BioFoam was used in a liver resection procedure following tumor removal as a supplemental measure to promote hemostasis (a complex process that stops bleeding) by sealing vessels.

"Despite advances in surgical technique, bleeding complications continue to be a problem in liver resection surgery and can be life-threatening," said Professor Brian Davidson, MD, FRCS, Professor of Surgery, Department of Surgery, Royal Free Hospital in London who performed the procedure on September 9. "We are very hopeful that BioFoam will reduce the time required to achieve hemostasis during liver resection surgery and will reduce the number of complications following surgery."

CryoLife is conducting a controlled clinical launch of BioFoam at up to six centers in the United Kingdom, Germany, France and Italy. The objectives of this 45-patient controlled launch, in which BioFoam is used as a surgical hemostatic adjunct in the open repair of liver parenchyma following liver resection and/or liver transplant surgery, are to (1) collect additional clinical data supporting the safety and performance of BioFoam and (2) further refine the optimal application technique.

"The clinical availability of BioFoam is another milestone in the company's corporate objective of providing world-class sur
'/>"/>

SOURCE CryoLife, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. CryoLifes Second Annual Surgical Congress for the Ross Procedure to Draw More than 130 Cardiovascular Surgeons from Around the World
2. CryoLife Announces Implants of First FDA-Cleared SynerGraft(R) Processed Human Cardiac Patch Material
3. CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Cardiac Patch Material
4. CryoLife Reports Record First Quarter Revenues of $26.7 Million
5. CryoLife Announces Release Date and Teleconference Call Details for 2009 First Quarter Financial Results
6. CryoLife to Present at Sidotis 13th Annual New York Emerging Growth Institutional Forum
7. CryoLife Reports Record Annual Revenues of $105.1 Million for FY 2008
8. CryoLife Announces Release Date and Teleconference Call Details for 2008 Fourth Quarter and Year End Financial Results
9. CryoLife, Inc. Receives Tissue From 100,000th Donor, Marking Industry Milestone
10. CryoLife to Present at 20th Annual Piper Jaffray Health Care Conference
11. CryoLifes Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... The report “Fragrance Ingredients Market by Type (Essential ... and Soaps & Detergents) & by Geography - Global ... the Fragrance Ingredients Market with analyses and projection of ... market has been segmented on the basis of major ... and Rest of the World (ROW); and their value ...
(Date:10/30/2014)... 2014 Deep Research Report on ... professional and in-depth research report on the China ... information, including its definition, classification, application, and industry ... research covers the international market analysis, including China’s ... covering macroeconomic environment & economic situation analysis. The ...
(Date:10/30/2014)... James Sherley says he has been working ... cell technology since his days as a principal investigator at ... late 1990’s. Sherley founded the ASCTC as a new ... the intellectual property developed in Sherley’s research over the years ... of Technology (MIT), and more recently as a senior scientist ...
(Date:10/30/2014)... Al Khaimah, UAE (PRWEB) October 30, 2014 ... appointment of Dr. James A. Manganello, Chairman of the Board, ... of The Bahamas. The appointment was made by the ... Bahamas on September 24th, 2014. , More than ... Therapy and Research Bill , Prime Minister Perry Christie said ...
Breaking Biology Technology:Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 2Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 3Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 4Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 5Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global, China Regions Now at DeepResearchReports.com 2Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global, China Regions Now at DeepResearchReports.com 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 2Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 4Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 2Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 3
... serious, hereditary ... bleeding disorder, found in region, KING OF PRUSSIA, Pa., ... Health and Medical Education (MOHME) has,granted rights to the company ... immediately. Haemate P is indicated for,the treatment of von Willebrand ...
... Special Protocol Assessment for Reviroc, AMSTERDAM, December ... successfully completed an End of Phase II meeting ... (FDA). Reviroc is under,development for elimination of cancer ... for end-stage blood cancer patients. The FDA,agreed that ...
... Avastin offers patients the chance to live twice as long without ... ... 19 Avastin (bevacizumab),Roche,s innovative anti-cancer drug, was approved today in ... (RCC) in,combination with interferon (IFN), the current standard of care*. Kidney,cancer, ...
Cached Biology Technology:CSL Behring Expands Into Middle East Market with Haemate(R) P 2CSL Behring Expands Into Middle East Market with Haemate(R) P 3Kiadis Pharma Reports Successful End of Phase II Meeting With FDA for Reviroc 2Avastin Approved in Europe for First-Line Treatment of Patients With Advanced Kidney Cancer 2Avastin Approved in Europe for First-Line Treatment of Patients With Advanced Kidney Cancer 3
(Date:10/31/2014)... creating green space in cities is good for attracting species, ... built environments, a University of Iowa study has found. , ... area in Iowa, and recorded the abundance of two insects ... plenty of the trees, black cherry and black walnut, they ... case fruit flies that feed on the walnuts and black ...
(Date:10/31/2014)... NEW YORK , Oct. 30, 2014 /PRNewswire-USNewswire/ ... lab, is pleased to announce its inaugural HITLAB ... at Columbia University,s Low Library. HITLAB will partner ... & Saatchi Wellness, Blueprint Health, ProtoHack, Columbia Business ... , and Columbia Industrial Engineering and Operations ...
(Date:10/30/2014)... 2014—Oligonucleotide-based therapeutics present unique challenges when it comes ... developmental harm. New consensus guidelines for toxicity testing ... biological characteristics of these novel biopharmaceuticals are presented ... journal from Mary Ann Liebert, Inc. publishers ... Nucleic Acid Therapeutics website until November ...
Breaking Biology News(10 mins):Green spaces don't ensure biodiversity in urban areas 2HITLAB Announces Inaugural HITLAB Innovators Summit 2HITLAB Announces Inaugural HITLAB Innovators Summit 3New guidelines for reproductive & developmental toxicity testing of oligonucleotide drugs 2
... from the Technische Universitaet Muenchen are to receive ... ten million euros to support pioneering research projects: ... impact of extreme weather events on ecosystems. Prof. ... for enhanced data processing. Prof. Rdiger Westermann (2.3M) ...
... world,s coastal marine ecosystems are being overlooked, both in ... a rallying point for conservation. Writing in Aquatic ... Dr. Amanda Vincent argues that increased protections are needed ... world,s oceans, where the richest diversity of marine habitats ...
... important biological processes. However, it is less efficient in ... use a slightly different mechanism and are thus more ... (MPIB) in Martinsried near Munich, Germany, have now identified ... red algae. "We could elucidate its structure and its ...
Cached Biology News:10 million euros for pioneering research projects at TU Muenchen 210 million euros for pioneering research projects at TU Muenchen 310 million euros for pioneering research projects at TU Muenchen 410 million euros for pioneering research projects at TU Muenchen 510 million euros for pioneering research projects at TU Muenchen 610 million euros for pioneering research projects at TU Muenchen 7Conservationists call for increased focus on coastal ecosystems 2Shoe strings and egg openers 2
... Yellow crystalline solid. PROTECT FROM LIGHT. Useful in ... required. Purity: ≥98% by TLC. Soluble in ... preparation of a 10 mM stock in DMSO is ... to H 2 O with rapid mixing (e.g. 10 ...
Monoclonal antibodies conjugated with rhodamine...
... Mouse monoclonal [RET-P1] to Rhodopsin Rhodopsin ... pigment in mammals, birds, amphibians, and reptiles. ... photoreceptor cells in the retina. ... retina. Specificity: This antibody ...
... 2HCl White to off-white ... inhibitor. Inhibits translation by causing premature ... DNA fragmentation in thymocytes and in ... ≥98% by TLC. Soluble in ...
Biology Products: